Laurent Audoly is a serial biotech entrepreneur and senior executive in the industry. Laurent has contributed to the identification and development of 7 novel approved medicines addressing unmet medical need across multiple disease areas that generate > $2B in annual sales. He serves as an independent board member (Cytovia, Vanderbilt). He is most recently founder of Parthenon Therapeutics, a precision oncology biotech operating at the intersection of systems biology, machine learning, pharmacology, and drug development to beat recalcitrant cancers. Prior to Parthenon, Laurent was at the helm of Kymera Therapeutics as its founding CEO, where he led the construction of the pipeline, platform, business, and partnerships. Earlier in his career, he held positions of increasing leadership responsibilities at Pfizer, Merck, and biotechs contributing to the advancement of 21 drug candidates. He is an inventor and authored over 70 papers and patents. He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and was the recipient of an American Heart Association Fellowship at Duke University.